Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 22.4× Spyre Therapeutics Inc. Common Stock's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is more actively traded (5,873,453 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| SYRE | VWO | |
|---|---|---|
Market Cap | $7.52B | $168.50B |
Volume | 1,441,031 | 5,873,453 |
Sector | Health | — |
52-Week High | $108.92 | $61.44 |
52-Week Low | $22.18 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VWO trades at $59.68, down slightly by 0.08% today. Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings are neutral. The ETF focuses on emerging markets, with exposure to Taiwan's AI and semiconductor sectors but faces headwinds from China's economic slowdown. Recent news highlights institutional buying interest, such as Allianz increasing its stake by 12.6% in Q3 2026.
Outlook is mixed: AI-driven growth in Taiwan offers upside, but China's weakness and concentration risks pose challenges. The ETF's low expense ratio of 0.06% appeals for cost-conscious investors, yet emerging market volatility requires caution. Key risks include regional economic instability and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
